FDA Approves Mylan’s Humira Biosimilar
Hulio Version Of Adalimumab Will Have To Wait Three Years To Launch
Mylan’s Hulio has become the sixth biosimilar version of Humira to be approved by the US FDA. However, all of these adalimumab biosimilars face a wait until 2023 before they can enter the market.
You may also be interested in...
Viatris and Fujifilm Kyowa Kirin Biologics have introduced Japan’s first biosimilar rival to Humira.
Merck & Co has disclosed more precise details around plans to spin off its more mature products, including biosimilars, into a new publicly traded company.
Mylan says it is closing in on $1bn in cumulative sales of its biosimilars, also disclosing its annual turnover figure from biosimilars as it reported its second-quarter results.